Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company dedicated to developing and providing transformative therapies for diseases with high unmet medical needs, utilizing its proprietary POD™ technology for intranasal drug delivery. The company focuses on CNS disorders such as migraine, Alzheimer’s, Parkinson’s, and schizophrenia, aiming to improve drug biodistribution and clinical outcomes through innovative nasal delivery platforms.
Industries
Nr. of Employees
medium (51-250)
Impel Pharmaceuticals
Patents
Products
Intranasal dihydroergotamine formulation delivered via precision olfactory device (INP104)
A combination of an approved dihydroergotamine formulation with a targeted intranasal delivery device designed to propel a narrow aerosol plume to the upper nasal cavity; developed to improve PK profile and offer a non-injectable alternative for acute migraine.
Intranasal levodopa delivery program (INP103)
Development program to deliver levodopa via a targeted intranasal device for potential treatment of Parkinson’s disease.
Intranasal insulin program for Alzheimer’s research (INP102)
Investigation of intranasal insulin delivery via targeted nasal device in an NIH-funded study to explore potential CNS effects relevant to Alzheimer’s disease.
Intranasal olanzapine program for agitation (INP105)
Program exploring intranasal delivery of antipsychotic medication for acute agitation in psychiatric disorders using targeted nasal delivery device technology.
Intranasal dihydroergotamine formulation delivered via precision olfactory device (INP104)
A combination of an approved dihydroergotamine formulation with a targeted intranasal delivery device designed to propel a narrow aerosol plume to the upper nasal cavity; developed to improve PK profile and offer a non-injectable alternative for acute migraine.
Intranasal levodopa delivery program (INP103)
Development program to deliver levodopa via a targeted intranasal device for potential treatment of Parkinson’s disease.
Intranasal insulin program for Alzheimer’s research (INP102)
Investigation of intranasal insulin delivery via targeted nasal device in an NIH-funded study to explore potential CNS effects relevant to Alzheimer’s disease.
Intranasal olanzapine program for agitation (INP105)
Program exploring intranasal delivery of antipsychotic medication for acute agitation in psychiatric disorders using targeted nasal delivery device technology.
Services
Collaborative regulatory planning and development support focused on pre-IND planning through NDA submissions, including use of the 505(b)(2) pathway via external consulting partnerships.
Collaborative licensing and partnership arrangements to enable external development of therapeutics using the intranasal delivery platform.
Collaborative regulatory planning and development support focused on pre-IND planning through NDA submissions, including use of the 505(b)(2) pathway via external consulting partnerships.
Collaborative licensing and partnership arrangements to enable external development of therapeutics using the intranasal delivery platform.
Expertise Areas
- Intranasal drug delivery
- Drug–device combination development
- Clinical trial management for PK and bioavailability studies
- Pharmacokinetics and bioanalytical assessment
Key Technologies
- Targeted upper nasal cavity deposition
- Aerosol nozzle and plume control engineering
- Dry powder and liquid intranasal formulation compatibility
- Intranasal drug–device combination platforms
News & Updates
Impel CEO, John Hoekman, attended the 35th annual JPM Healthcare Conference in San Francisco, CA.
Impel’s CEO, Jon Congleton, presented at the Neurotech Investing and Partnering Conference in San Francisco, CA.
Nyssa Liebermann and Sutapa Ray attended BIO in San Diego.
Impel’s CEO, Jon Congleton, CSO, Dr. John Hoekman, and CMO, Dr. Stephen Shrewsbury, presented at Cowen’s conference in Boston, MA.
Dr. John Hoekman presented at the Life Science Innovation Northwest 2018 in Seattle, WA.
Impel NeuroPharma received a new patent (number 9,919,117) for its POD™ device from the USPTO.
Impel CEO, John Hoekman, attended the 35th annual JPM Healthcare Conference in San Francisco, CA.
Impel’s CEO, Jon Congleton, presented at the Neurotech Investing and Partnering Conference in San Francisco, CA.
Nyssa Liebermann and Sutapa Ray attended BIO in San Diego.
Impel’s CEO, Jon Congleton, CSO, Dr. John Hoekman, and CMO, Dr. Stephen Shrewsbury, presented at Cowen’s conference in Boston, MA.
Dr. John Hoekman presented at the Life Science Innovation Northwest 2018 in Seattle, WA.
Impel NeuroPharma received a new patent (number 9,919,117) for its POD™ device from the USPTO.